{"entity":{"id":"chemistry-manufacturing-controls","kind":"term","name":"Chemistry, manufacturing and controls","aka":["chemistry manufacturing and controls","CMC quality information"],"tldr":"This is the evidence describing a product, how it is made and how its quality is controlled. It addresses product questions alongside the separate evidence about clinical outcomes.","summary":"FDA guidance for human gene-therapy investigational applications describes information intended to assure product safety, identity, quality, purity and strength, including potency. The potency-assurance guidance further connects manufacturing design, controls and testing. These sources have defined product and regulatory scopes. A manufacturing dossier, a laboratory release result and evidence that an intervention improves clinical outcomes are related but distinct parts of product development. ICH Q6B defines a specification as a list of tests, references to analytical procedures and appropriate acceptance criteria. FDA's May 2026 guidance on CMC flexibilities for cellular and gene therapy biologics licence applications is issued for immediate implementation and says its flexible approaches are not an exhaustive list, so flexibility depends on product and stage and is not an exemption.","asOf":"2026-11-10","links":[{"label":"FDA: chemistry, manufacturing and control information for human gene therapy INDs","url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chemistry-manufacturing-and-control-cmc-information-human-gene-therapy-investigational-new-drug"},{"label":"FDA: Potency Assurance for Cellular and Gene Therapy Products, final guidance (November 2026)","url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-potency-assurance-cellular-and-gene-therapy-products"},{"label":"FDA/ICH Q6B: specifications (August 1999)","url":"https://www.fda.gov/media/71510/download"},{"label":"FDA: CMC flexibilities for human cellular and gene therapy products for a biologics license application (May 2026)","url":"https://www.fda.gov/media/192321/download"},{"label":"FDA: final Potency Assurance for Cellular and Gene Therapy Products (November 2026 PDF)","url":"https://www.fda.gov/media/196183/download"},{"label":"Federal Register: final potency-assurance guidance, 3 November 2026","url":"https://www.federalregister.gov/documents/2026/11/03/2026-22427/potency-assurance-for-cellular-and-gene-therapy-products-guidance-for-industry-availability"}],"tags":[],"related":["certificate-of-analysis","manufacturing-process-comparability","cell-therapy-release-testing","mrna-lnp-manufacturing"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["CMC is the product-quality evidence: what the product is, how it is made and how its important features are checked. For living-cell and gene products chemistry is not restricted to chemical measurements; FDA's January 2020 gene-therapy CMC guidance covers product description, manufacture, specifications and stability for investigational applications. A facility's GMP framework, a dossier and a lot's release decision are different things.","Critical quality attributes (CQAs) are product characteristics kept within justified limits, and the 2020 guidance says establishing them early matters because comparability by analytical methods depends on them. A processing setting and the product attribute it affects are related but are not the same measurement. ICH Q6B defines a specification as a list of tests, references to analytical procedures and acceptance criteria.","Identity and potency answer different questions. FDA's 1999 vaccine CMC guidance asks for characterisation with respect to identity, purity, potency and stability, and FDA's November 2026 potency guidance expects the relationship between a measured attribute and the product's mechanism of action to be supported.","Stability asks whether quality persists under stated storage, transport and use conditions. The 2020 guidance asks for stability protocols, data, storage conditions and shelf life. A result at manufacture, or one time point, does not cover every later journey. Q5E notes that stability studies can detect subtle differences not seen at release.","Changes need assessment of whether earlier evidence still applies. FDA's CAR T guidance says showing that changed product meets current lot-release criteria is typically insufficient to establish comparability. A dossier written for one version cannot simply be relabelled for a changed formulation, even if the sequence is shared.","Evidence develops with the program. FDA's May 2026 CMC-flexibilities guidance, issued for immediate implementation, addresses cell and gene products moving toward a biologics licence application and states that its flexible approaches are not an exhaustive list. Flexibility depends on product and stage and is not an exemption from quality requirements; an investigational submission and a marketing application are different review settings."],"category":"Regulation & policy"},"route":"/terms/chemistry-manufacturing-controls/","neighbours":{"term":[{"id":"certificate-of-analysis","kind":"term","name":"Certificate of analysis","route":"/terms/certificate-of-analysis/"},{"id":"manufacturing-process-comparability","kind":"term","name":"Comparability after manufacturing changes","route":"/terms/manufacturing-process-comparability/"},{"id":"dsrna-impurities","kind":"term","name":"Double-stranded RNA impurities","route":"/terms/dsrna-impurities/"},{"id":"immune-product-evidence","kind":"term","name":"Immune measurements and product evidence","route":"/terms/immune-product-evidence/"},{"id":"in-vitro-transcription","kind":"term","name":"In vitro transcription for RNA products","route":"/terms/in-vitro-transcription/"},{"id":"vein-to-vein-time","kind":"term","name":"Vein-to-vein time and manufacturing slots","route":"/terms/vein-to-vein-time/"}],"technology":[{"id":"cell-therapy-release-testing","kind":"technology","name":"Cell-therapy release and potency testing","route":"/technologies/cell-therapy-release-testing/"},{"id":"mrna-lnp-manufacturing","kind":"technology","name":"mRNA and lipid nanoparticle manufacturing","route":"/technologies/mrna-lnp-manufacturing/"}]}}